The PULMAtech Universal Introducer Sheath design will be intended to increase the adaptability of Edwards Lifesciences TAVR procedure to better serve patients requiring alternative access.

TAVR is the standard of care to treat AS, with more than 90,000 cases each yearThe current market size for TAVR procedures is listed at 5.25 billion dollars and the projected market value is said to increase to be about 12 billion dollars by 2028.

Our business model involves creating a low-cost device sold within the original Edwards packaging. This is an effective model because it would be more cost-efficient to package the components of our product with Edwards Lifesciences TAVR device. The operators can determine, if necessary, if our parts are needed for a possible alternative access procedure.

Our primary competitors are Medtronic, LivaNova and CryoLife. Although there are currently no products on the market that are designed to address the introducer sheath issue during alternative access, many companies are currently attempting to make products to address this issue. Furthermore, none of the companies have yet to produce a viable product.